摘要
目的分析糖尿病视网膜病变伴黄斑水肿患者接受二甲双胍、曲安奈德联合康柏西普干预的效果。方法回顾性选取2022年6月—2024年5月常熟市第一人民医院收治的90例糖尿病视网膜病变伴黄斑水肿患者的临床资料,依据治疗方式分对照组、观察组,各45例。对照组实施二甲双胍、曲安奈德干预,观察组在对照组基础上联合康柏西普干预。对比两组血糖指标、胰岛素样生长因子1和最佳矫正视力。结果干预后,观察组空腹血糖、糖化血红蛋白、胰岛素样生长因子1水平均低于对照组,但差异均无统计学意义(P均>0.05)。干预后3个月、干预6个月观察组最佳矫正视力分别为(0.50±0.07)LogMAR、(0.59±0.11)LogMAR,均高于对照组的(0.46±0.10)LogMAR、(0.54±0.09)LogMAR,差异均有统计学意义(t=2.198,2.360;P均<0.05)。结论康柏西普能够通过抑制血管内皮生长因子进一步改善患者最佳矫正视力,但仅能够通过改善眼底局部代谢微环境间接辅助血糖控制,无法促进血糖指标、胰岛素样生长因子1水平改善。
Objective To analyze the intervention effect of metformin,triamcinolone acetonide combined with conbercept in patients with diabetic retinopathy and macular edema.Methods The clinical data of 90 patients with diabetic retinopathy and macular edema admitted to Changshu First People's Hospital from June 2022 to May 2024 were retrospectively selected.According to the treatment methods,they were divided into control group and observation group,with 45 cases in each group.The control group received metformin and triamcinolone acetonide intervention,and the observation group was combined with compacept intervention on the basis of the control group.The blood glucose index,insulin-like growth factor 1 and best corrected visual acuity were compared between the two groups.Results After intervention,the fasting plasma glucose,glycated hemoglobin A1c and insulin-like growth factor 1 in the observation group were lower than those in the control group,but the differences were not statistically significant(all P>0.05).At 3 months and 6 months after intervention,the best corrected visual acuity of the observation group was(0.50±0.07)LogMAR and(0.59±0.11)LogMAR,respectively,which were higher than(0.46±0.10)LogMAR and(0.54±0.09)Log‑MAR of the control group,and the differences were statistically significant(t=2.198,2.360;both P<0.05).Conclusion Conbercept can further improve the best corrected visual acuity of patients by inhibiting vascular endothelial growth factor,but it can only indirectly assist blood glucose control by improving the local metabolic microenvironment of the fundus,and cannot significantly promote the improvement of blood glucose index and insulin-like growth factor 1 level.
作者
韦立群
WEI Liqun(Department of Ophthalmology,Changshu First People's Hospital,Changshu 215500,Jiangsu,China)
出处
《糖尿病新世界》
2025年第21期97-100,共4页
Diabetes New World
